Medicare AdvantagePrior AuthMedium impact
Camcevi (leuprolide mesylate) (Revised)
Humana·Oncology, Urology·Medicare Advantage
Effective date
Jan 1, 2026
We identified it
Jun 24, 2026
Summary
Humana Medicare Advantage now requires prior authorization for Camcevi (leuprolide mesylate) subcutaneous injections for advanced prostate cancer treatment. Members must meet specific diagnosis criteria and cannot use other LHRH analogs concurrently.
Action Required
By January 1, 2026: Billing team must obtain prior authorization from Humana Medicare Advantage before administering Camcevi (leuprolide mesylate) for prostate cancer patients. Verify patient has advanced prostate cancer diagnosis and is not using other LHRH analogs. Visit www.humana.com/PAL for specific medical billing codes and preauthorization requirements. Claims will be denied without prior authorization.